article thumbnail

Ascendis Pharma submits sBLA for growth hormone deficiency therapy

Pharmaceutical Technology

Ascendis Pharma has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for TransCon hGH to treat adults with growth hormone deficiency (GHD).

Hormones 147
article thumbnail

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

Bio Pharma Dive

The findings, from two trials involving tens of thousands of women, could influence guidelines around the use of hormonal treatment for menopausal symptoms.

Hormones 293
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions

Pharmaceutical Technology

Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and SSTR2 activity regulation.

Hormones 130
article thumbnail

Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

Hormones 130
article thumbnail

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

Fierce Pharma

After two delays, the FDA has finally signed off on Ascendis Pharma's hormone replacement therapy Yorvipath, also known as TransCon PTH, which is the first approved product for hypoparathyroidism in adults in the U.S. Ascendis Pharma should be well prepared for the U.S.

Hormones 112
article thumbnail

Abiraterone acetate by Tavanta Therapeutics for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

Hormones 130
article thumbnail

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer by Cellbion for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Pharmaceutical Technology

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hormones 130